Efstathios Kastritis, MD, on Implications of Positive Results From the Phase 3 ANDROMEDA Study

Video

The phase 3 ANDROMEDA trial demonstrated positive efficacy and safety data in the treatment of newly diagnosed light chain amyloidosis.

At the 2021 American Society for Clinical Oncology (ASCO) Annual Meeting, CancerNetwork® sat down with Efstathios Kastritis, MD, professor of medical oncology at the National and Kapodistrian University of Athens, in Athens, Greece, to discuss the phase 3 ANDROMEDA trial (NCT03201965). The expert detailed what these results mean for the treatment of patients with newly diagnosed light chain (AL) amyloidosis with subcutaneous daratumumab (DARA; Darzalex) plus bortezomib (Velcade), cyclophosphamide, and dexamethasone (VCd) moving forward.

Transcription:

Based on the results of the ANDROMEDA study, the combination of daratumumab with VCd has become the first official approved therapy for AL amyloidosis. So first of all, our patients will finally have a very effective therapy that is also quite safe since we didn’t see any additional safety signals with the combinations with the addition of daratumumab to VCd.

The improvement in the complete hematologic response rates is very important because we know that this is the most important factor associated with the improvement in overall survival and also with improvement in organ function. Actually, this is where we see a doubling of organ response rates, which probably will further improve in the future.

Reference

Kastritis E, Sanchorawala V, Merlini G, et al. Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study. J Clin Oncol. 2021;39(suppl 15):8003. doi:10.1200/JCO.2021.39.15_suppl.8003

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“If you have a [patient in the] fourth or fifth line, [JNJ-5322] could be a valid drug of choice,” said Rakesh Popat, BSc, MBBS, MRCP, FRCPath, PhD.
Earlier treatment with daratumumab may be better tolerated for patients with pretreated MRD-negative multiple myeloma.
The trispecific antibody JNJ-5322 demonstrated superior efficacy vs approved agents in multiple myeloma in results shared at the 2025 EHA Congress.
Despite CD19 CAR T-cell therapy exhibiting efficacy in patients with relapsed/refractory large B-cell lymphoma, less than half achieve long-term remission.
Current findings from the phase 1/2 CaDAnCe-101 trial show no predictive factors of improved responses with BGB-16673 in patients with CLL or SLL.
More follow-up data will better elucidate the impact of frontline use of hypomethylating agents in patients with myelodysplastic syndromes.
Related Content